Epicardial Injection of Allogeneic Human Pluripotent Stem Cell-derived Cardiomyocytes to Treat Severe Chronic Heart Failure
Latest Information Update: 27 Nov 2023
At a glance
- Drugs HiCM 188 (Primary)
- Indications Heart failure
- Focus Adverse reactions
- Sponsors Help Therapeutics
- 21 Nov 2023 Status changed from not yet recruiting to recruiting.
- 12 Oct 2022 Planned initiation date changed from 30 Sep 2022 to 30 Oct 2022.
- 07 Oct 2022 New trial record